Chiara Cremolini

Research interests

Publications

• Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

  Cell · 2024 · https://doi.org/10.1016/j.cell.2024.05.029

• Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2308795

• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00150-x

• Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00772-9

• Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2214963

• Treatment of Metastatic Colorectal Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.01690

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0894-7

• Quantitative evidence for early metastatic seeding in colorectal cancer

  Nature Genetics · 2019 · https://doi.org/10.1038/s41588-019-0423-x

• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.5080

• ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

  JNCI Journal of the National Cancer Institute · 2017 · https://doi.org/10.1093/jnci/djx089

• Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

  Nature Medicine · 2015 · https://doi.org/10.1038/nm.3870

• FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00122-9

• Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1403108

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  British Journal of Cancer · 2009 · https://doi.org/10.1038/sj.bjc.6605177

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

Current projects

No projects listed.